존슨앤드존슨(얀센) 임상시험
-
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
-
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Di
-
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non
-
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
-
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With
-
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Pre
-
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
-
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-B
-
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CR
-
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
-
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
-
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
-
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Vi
-
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
-
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-T
기업별 임상
화이자머크(MSD)로슈노바티스아스트라제네카존슨앤드존슨(얀센)BMS사노피GSK일라이 릴리애브비암젠바이엘베링거인겔하임노보 노디스크다케다길리어드모더나바이오엔테크리제네론버텍스바이오젠다이이찌산쿄아스텔라스에자이오츠카세르비에인사이트셀트리온삼성바이오에피스한미약품유한양행